Blueprint Medicines

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 655

Market Cap: $5.8B

Website

Introduction: Blueprint Medicines Corp. is a precision therapy company, which engages in the invention of medicines for people with cancer and blood disorders. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Clinical Trials

Study of Elenestinib (BLU-263) in Advanced Systemic Mastocytosis (AdvSM) and and Other KIT Altered Hematologic Malignancies

Phase 1

Recruiting

Conditions: Advanced Systemic Mastocytosis

Interventions: Drug: BLU-263
Drug: Azacitidine

First Posted Date: 2022-11-08

Last Posted Date: 2024-04-02

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 67

Registration Number: NCT05609942

Locations: 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇩🇪
University Medical Centre Mannheim, Mannheim, Germany
🇺🇸
Stanford Cancer Institute, Palo Alto, California, United States

and more 8 locations

(VELA) Study of BLU-222 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: HR+ Breast Cancer
Carcinosarcoma
Advanced Solid Tumors
CCNE1 Amplification
HER2-negative Breast Cancer
Gastric Cancer
Esophageal Adenocarcinoma
Ovarian Cancer
Endometrial Cancer

Interventions: Drug: BLU-222
Drug: Ribociclib
Drug: Carboplatin
Drug: Fulvestrant

First Posted Date: 2022-02-23

Last Posted Date: 2024-04-23

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 366

Registration Number: NCT05252416

Locations: 🇺🇸
Hospital of the Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States

and more 20 locations

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Phase 1

Active, not recruiting

Conditions: Lung Neoplasm Malignant
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Disease
Carcinoma, Bronchogenic
Bronchial Neoplasms
Adenocarcinoma

Interventions: Drug: BLU-451
Drug: Carboplatin
Drug: Pemetrexed

First Posted Date: 2022-02-16

Last Posted Date: 2024-01-16

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 332

Registration Number: NCT05241873

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
City of Hope (City of Hope National Medical Center, City of Hope Medical Center), Duarte, California, United States
🇯🇵
National Cancer Center Hospital East, Kashiwa, Chiba, Japan

and more 20 locations

(HARMONY) Study of BLU-701 in EGFR-mutant NSCLC

Phase 1

Terminated

Conditions: Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Respiratory Tract Diseases
EGFR C797S
Bronchial Neoplasms
Neoplasms by Histologic Type
Lung Neoplasm
Carcinoma, Bronchogenic

Interventions: Drug: BLU-701
Drug: carboplatin
Drug: osimertinib
Drug: pemetrexed

First Posted Date: 2021-12-10

Last Posted Date: 2023-06-18

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 20

Registration Number: NCT05153408

Locations: 🇺🇸
Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 4 locations

(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis

Phase 2

Recruiting

Conditions: Smoldering Systemic Mastocytosis
Indolent Systemic Mastocytosis
Monoclonal Mast Cell Activation Syndrome

Interventions: Drug: Elenestinib
Drug: Placebo

First Posted Date: 2021-06-02

Last Posted Date: 2024-11-11

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 463

Registration Number: NCT04910685

Locations: 🇫🇷
CHU Grenoble, Grenoble Cedex 9, France
🇫🇷
CHU de Limoges, Limoges Cedex, France
🇫🇷
CHU de Nantes, Nantes, France

and more 48 locations

A Drug-drug Interaction Study of Avapritinib and Midazolam

Phase 1

Completed

Conditions: Recurrent or Unresectable Central Nervous System (CNS) Tumors
Gastrointestinal Stromal Tumors
GIST
Non-resectable Advanced Solid Tumors

Interventions: Drug: Avapritinib
Drug: midazolam

First Posted Date: 2021-06-01

Last Posted Date: 2024-12-13

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 10

Registration Number: NCT04908176

Locations: 🇺🇸
Mayo Clinic Florida, Jacksonville, Florida, United States
🇺🇸
Thomas Jefferson University, Sidney Kimmel Cancer Center, Philadelphia, Pennsylvania, United States
🇺🇸
University of Michigan, Ann Arbor, Michigan, United States

(SYMPHONY) Phase 1/2 Study Targeting EGFR Resistance Mechanisms in NSCLC

Phase 1

Active, not recruiting

Conditions: Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Respiratory Tract Neoplasms
Neoplasms
Neoplasms by Site
Lung Diseases
Respiratory Tract Disease
Carcinoma, Bronchogenic
Bronchial Neoplasms
Adenocarcinoma

Interventions: Drug: BLU-945
Drug: osimertinib

First Posted Date: 2021-04-28

Last Posted Date: 2024-01-12

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 190

Registration Number: NCT04862780

Locations: 🇫🇷
Institut Claudius Regaud (IUCT-O) - Cancer Comprehensive Center, Toulouse, France
🇨🇦
Princess Margaret Cancer Centre, Toronto, Ontario, Canada
🇯🇵
National Cancer Center Hospital, Chuo Ku, Tokyo, Japan

and more 23 locations

Study for Patients Previously Treated in Avapritinib Clinical Trials

Phase 4

Completed

Conditions: Gastrointestinal Stromal Tumors

Interventions: Drug: Avapritinib

First Posted Date: 2021-04-01

Last Posted Date: 2024-11-26

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 2

Registration Number: NCT04825574

Locations: 🇫🇷
Gustave Roussy Cancer Campus Grand Paris Institut de Cancerologie Gustave-Roussy, Villejuif, Val-de-Marne, France

(PROSPECTOR) Screening Study Evaluating the Prevalence of the KIT D816V Mutation in Patients With Systemic Mast Cell Activation

Completed

Conditions: Systemic Mast Cell Activation
KIT D816V Mutation

First Posted Date: 2021-03-23

Last Posted Date: 2023-04-06

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 379

Registration Number: NCT04811365

Locations: 🇺🇸
Scripps Clinic Carmel Valley, San Diego, California, United States
🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸
Duke University: Duke Allergy Asthma Airway Center, Durham, North Carolina, United States

and more 20 locations

A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling

Phase 1

Recruiting

Conditions: Solid Tumor, Unspecified, Child
Relapsed Solid Neoplasm
CNS Tumor

Interventions: Drug: avapritinib

First Posted Date: 2021-02-26

Last Posted Date: 2023-06-15

Lead Sponsor: Blueprint Medicines Corporation

Target Recruit Count: 37

Registration Number: NCT04773782

Locations: 🇫🇷
Gustave Roussy, Villejuif, France
🇩🇪
Universitaetsmedizin Göttingen, Göttingen, Lower Saxony, Germany
🇩🇪
Hopp Children's Cancer Center, Heidelberg, Germany

and more 23 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy